Myokardia Inc., of South San Francisco, Calif., said it priced an underwritten public offering of 3.8 million shares of its common stock at $15 each. In addition, the underwriters have a 30-day option to purchase up to an additional 570,000 shares of common stock. Credit Suisse Securities (USA) LLC and Cowen and Co. are acting as joint lead book-running managers for the offering. BMO Capital Markets Corp. is acting as book-running manager. Wedbush Securities Inc. is acting as co-manager. Read More

Roche AG, of Basel, Switzerland, said Rheumatology and Therapy published a study assessing the long-term safety and efficacy of subcutaneous (SC) Actemra (tocilizumab) in patients with rheumatoid arthritis (RA) previously enrolled in the SUMMACTA and BREVACTA trials. Read More

Daiichi Sankyo Co. Ltd., of Tokyo, agreed to acquire a license to the Azymetric and Effector Function Enhancement and Control Technology , or EFECT, platforms developed by Zymeworks Inc., of Vancouver, British Columbia, to develop a bispecific antibody. Read More

The National Heart, Lung and Blood Institute, part of the U.S. NIH, is seeking comment on its draft national action plan aimed at helping stakeholders reduce the burden of chronic obstructive pulmonary disease (COPD). Read More

In drama that could only be rivaled by a telenovela, last week the FDA approved Sarepta Therapeutics Inc.'s Duchenne muscular dystrophy (DMD) drug, eteplirsen, branded Exondys 51. Read More

By combining two materials that are frequently used in surgical procedures, researchers at Northwestern University have created a synthetic "hyperelastic bone" material that could be printed via 3-D printers into shapes that could be further processed "on the fly" in the operating room. Read More

LONDON – U.S. researchers based at New Hope Fertility Center in New York have announced the first baby born using spindle nuclear transfer (SNT) mitochondrial donation has been delivered safe and well at a clinic in Mexico. Read More

DUBLIN – 4SC AG has spun out its immunology arm into a new startup, Immunic AG, which has raised €17.5 million (US$19.6 million) in a series A round to take forward two programs in autoimmune disease. Read More

DUBLIN – Shareholders in Viratherapeutics GmbH could be in line for a big payday as the company has entered a development and option agreement with Boehringer Ingelheim GmbH worth up to €210 million (US$235 million). Read More